Suppr超能文献

羧酰胺脾酪氨酸激酶(Syk)抑制剂:利用基态相互作用加速优化

Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.

作者信息

Ellis J Michael, Altman Michael D, Cash Brandon, Haidle Andrew M, Kubiak Rachel L, Maddess Matthew L, Yan Youwei, Northrup Alan B

机构信息

Department of Discovery Chemistry, Merck & Co., Inc. , 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.

出版信息

ACS Med Chem Lett. 2016 Oct 7;7(12):1151-1155. doi: 10.1021/acsmedchemlett.6b00353. eCollection 2016 Dec 8.

Abstract

Optimization of a series of highly potent and kinome selective carbon-linked carboxamide spleen tyrosine kinase (Syk) inhibitors with favorable drug-like properties is described. A pervasive Ames liability in an analogous nitrogen-linked carboxamide series was obviated by replacement with a carbon-linked moiety. Initial efforts lacked on-target potency, likely due to strain induced between the hinge binding amide and solvent front heterocycle. Consideration of ground state and bound state energetics allowed rapid realization of improved solvent front substituents affording subnanomolar Syk potency and high kinome selectivity. These molecules were also devoid of mutagenicity risk as assessed via the Ames test using the TA97a strain.

摘要

本文描述了一系列具有良好类药性质的高效且激酶组选择性碳连接羧酰胺脾酪氨酸激酶(Syk)抑制剂的优化过程。通过用碳连接部分取代,消除了类似氮连接羧酰胺系列中普遍存在的艾姆斯致突变性。最初的努力缺乏靶点活性,这可能是由于铰链结合酰胺和溶剂前沿杂环之间的应变所致。对基态和结合态能量学的考虑使得能够快速实现改进的溶剂前沿取代基,从而提供亚纳摩尔级别的Syk活性和高激酶组选择性。通过使用TA97a菌株的艾姆斯试验评估,这些分子也没有致突变风险。

相似文献

1
Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.
ACS Med Chem Lett. 2016 Oct 7;7(12):1151-1155. doi: 10.1021/acsmedchemlett.6b00353. eCollection 2016 Dec 8.
2
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
J Med Chem. 2015 Feb 26;58(4):1929-39. doi: 10.1021/jm5018169. Epub 2015 Feb 16.
3
Rational design of highly selective spleen tyrosine kinase inhibitors.
J Med Chem. 2012 Dec 13;55(23):10414-23. doi: 10.1021/jm301367c. Epub 2012 Nov 27.
4
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
Chem Biol Drug Des. 2009 Apr;73(4):466-70. doi: 10.1111/j.1747-0285.2009.00785.x. Epub 2009 Feb 7.
7
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors.
RSC Med Chem. 2021 Jun 4;12(7):1164-1173. doi: 10.1039/d1md00097g. eCollection 2021 Jul 21.
8
Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors.
Bioorg Med Chem Lett. 2016 Oct 1;26(19):4606-4612. doi: 10.1016/j.bmcl.2016.08.070. Epub 2016 Aug 23.
9
Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
Bioorg Med Chem Lett. 2016 Nov 15;26(22):5562-5567. doi: 10.1016/j.bmcl.2016.09.077. Epub 2016 Oct 11.
10
Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Bioorg Med Chem Lett. 2015 Oct 15;25(20):4441-6. doi: 10.1016/j.bmcl.2015.09.011. Epub 2015 Sep 8.

引用本文的文献

1
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.
ACS Med Chem Lett. 2021 Mar 19;12(4):653-661. doi: 10.1021/acsmedchemlett.1c00096. eCollection 2021 Apr 8.
2
Indolylboronic Acids: Preparation and Applications.
Molecules. 2019 Sep 28;24(19):3523. doi: 10.3390/molecules24193523.

本文引用的文献

1
Discovery and profiling of a selective and efficacious Syk inhibitor.
J Med Chem. 2015 Feb 26;58(4):1950-63. doi: 10.1021/jm5018863. Epub 2015 Feb 9.
2
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
J Med Chem. 2015 Feb 26;58(4):1929-39. doi: 10.1021/jm5018169. Epub 2015 Feb 16.
3
Getting Syk: spleen tyrosine kinase as a therapeutic target.
Trends Pharmacol Sci. 2014 Aug;35(8):414-22. doi: 10.1016/j.tips.2014.05.007. Epub 2014 Jun 26.
4
Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
J Med Chem. 2014 May 8;57(9):3856-73. doi: 10.1021/jm500228a. Epub 2014 Apr 29.
7
Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.
Am J Respir Cell Mol Biol. 2013 Dec;49(6):1085-92. doi: 10.1165/rcmb.2013-0200OC.
10
Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
Bioorg Med Chem Lett. 2011 Oct 15;21(20):6188-94. doi: 10.1016/j.bmcl.2011.07.082. Epub 2011 Aug 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验